1. Home
  2. Faculty

Saima Sharif, MD, MS

Clinical Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation

Current Positions

  • Clinical Professor of Internal Medicine-Hematology, Oncology, and Blood & Marrow Transplantation
  • Medical Director, Holden Comprehensive Cancer Center, University of Iowa Health Care
  • Medical Director, 4 John Colloton Unit, University of Iowa Hospitals & Clinics

Education

  • MD, Dow Medical College, University of Karachi, Pakistan, Karachi, Pakistan
  • MS, Clinical Research (Clinical Epidemiology Track), University of Pittsburgh, Pittsburgh, Pennsylvania
  • Resident, Internal Medicine, The North Shore Medical Center, Salem Hospital, Tufts University, MEdford, Massachusetts
  • Fellow, Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Selected Publications

  • O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. (2014). Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 32 (18) 1927–1934. DOI: 10.1200/JCO.2013.53.7753. PMID: 24799484.
  • Yothers G, O’Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N. (2013). Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31 (36) 4512–4519. DOI: 10.1200/JCO.2012.47.3116. PMID: 24220557.
  • Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, Blackmon N, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O’Connell MJ, Wolmark N, Paik S. (2013). Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. Journal of the National Cancer Institute 105 (13) 989–992. DOI: 10.1093/jnci/djt140. PMID: 23821759.
  • Allegra, C. J., Yothers, G., O’Connell, M. J., Sharif, S., Petrelli, N. J., Lopa, S. H. & Wolmark, N. (2013). Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31 (3) 359–364. DOI: 10.1200/JCO.2012.44.4711. PMID: 23233715.
  • McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, Wagman LD, O’Connell MJ, Wolmark N. (2012). Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30 (26) 3223–3228. DOI: 10.1200/JCO.2012.42.4044. PMID: 22869888.
  • Sharif S, O’Connell MJ. (2012). Gene Signatures in Stage II Colon Cancer: A Clinical Review. Current Colorectal Cancer Reports 8 (3) 225–231. DOI: 10.1007/s11888-012-0132-7. PMID: 23002390.
  • Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O’Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. (2011). Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29 (1) 11–16. DOI: 10.1200/JCO.2010.30.0855. PMID: 20940184.
  • Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O’Reilly S, Chu L, Azar CA, Wolmark N. (2009). Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27 (20) 3385–3390. DOI: 10.1200/JCO.2009.21.9220. PMID: 19414665.
  • Smith LM, Sharif S, Brand R, Fink E, Lamb J, Whitcomb DC. (2009). MUTYH exon 7 and 13 mutations associated with colorectal cancer (MAP syndrome) are not commonly associated with sporadic pancreatic cancer. Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.] 9 (6) 793–796. DOI: 10.1159/000199440. PMID: 20110747.
  • Sharif S, Ramanathan RK, Potter D, Cieply K, Krasinskas AM. (2008). HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Digestive Diseases and Sciences 53 (11) 3026–3032. DOI: 10.1007/s10620-008-0267-1. PMID: 18463983.